pharmaceutical investing Corbus Pharmaceuticals to Commence Phase 3 Study of Lenabasum for the Treatment of Rare Autoimmune Disease Dermatomyositis
pharmaceutical investing Corbus Pharmaceuticals Receives FDA Orphan Drug Designation for Lenabasum for the Treatment of Dermatomyositis
Copper Intelligence and CoTec Finalise Joint Venture Shareholder Agreement to Target Processing Historical Copper Tailings Opportunities in the Democratic Republic of Congo
Edgewater Wireless Reports First Quarter Fiscal 2027 Results and Advances PrismIQ Commercialization Roadmap
